Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.
Selnick
H G
HG
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Liverton
N J
NJ
Baldwin
J J
JJ
Butcher
J W
JW
Claremon
D A
DA
Elliott
J M
JM
Freidinger
R M
RM
King
S A
SA
Libby
B E
BE
McIntyre
C J
CJ
Pribush
D A
DA
Remy
D C
DC
Smith
G R
GR
Tebben
A J
AJ
Jurkiewicz
N K
NK
Lynch
J J
JJ
Salata
J J
JJ
Sanguinetti
M C
MC
Siegl
P K
PK
Slaughter
D E
DE
Vyas
K
K
D000081:Acetamides / Q000138:chemical synthesis* / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000138:chemical synthesis* / Q000494:pharmacology*; D002478:Cells, Cultured; D004285:Dogs; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009206:Myocardium / Q000166:cytology; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000502:physiology; D014981:Xenopus
D000081:Acetamides; D000889:Anti-Arrhythmia Agents; D001570:Benzodiazepinones; C109598:L 768673; D026902:Potassium Channel Blockers; D015221:Potassium Channels